Advanced search

Vol 52, No 4 (2021)
Review article
Published online: 2021-08-31

open access

View PDF Download PDF file
Page views 575
Article views/downloads 311
Get Citation

Connect on Social Media

Connect on Social Media

Primary central nervous system lymphoma in neurosurgery

Dariusz Szczepanek1, Filip Stoma1, Aleksandra Szczepanek2
DOI: 10.5603/AHP.2021.0067
Acta Haematol Pol 2021;52(4):349-354.

Abstract

Primary central nervous system lymphoma (PCNSL) most commonly (>95%) constitutes a specific kind of diffuse large B-cell lymphoma, which shows expression of CD20, CD19 and CD79a antigens on its surface and belongs to non-germinal center B-cell-like type (non-GCB). This results from both its limited localization as well as immunophenotypic and molecular features. It frequently has an aggressive clinical course and its prognosis remains highly uncertain.

PCNSL’s development in areas normally free from lymphoid tissue has not been adequately explained thus far. PCNSL is usually a solitary lesion (60–70%), with the majority (c.60%) occurring in supratentorial areas, and less frequently in telencephalic nuclei and periventricular areas, corpus callosum, infratentorial structures, spinal cord or orbital cavities. Lymphoid cells can occasionally create diffuse infiltration with no mass effect — a PCNSL variant known as lymphomatosis cerebri. Reported clinical symptoms depend on the localization of the tumor in central nervous system. The most common include: cognitive impairment, behavioral changes, focal neurological deficit and symptoms of increased intracranial pressure. A final diagnosis of PCNSL requires histopathological evaluation of tissue samples obtained usually during a stereotactic biopsy. Identifying lymphoid cells in cerebrospinal fluid may also be sufficient. Chemotherapy combined with radiotherapy is the standard treatment of PCNSL. For many years, surgical treatment has been controversial. This provides constant encouragement to explore effective treatment methods, with neurosurgical involvement waiting to be further defined.

Keywords: primary central nervous lymphomaPCNSL

Article available in PDF format

View PDF Download PDF file

References

  1. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002; 95(7): 1504–1510.
    CrossRefPubMed
  2. Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011; 105(9): 1414–1418.
    CrossRefPubMed
  3. Giannini C, Dogan A, Salomão DR. CNS lymphoma: a practical diagnostic approach. J Neuropathol Exp Neurol. 2014; 73(6): 478–494.
    CrossRefPubMed
  4. Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006; 107(1): 190–196.
    CrossRefPubMed
  5. Montesinos-Rongen M, Brunn A, Bentink S, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia. 2008; 22(2): 400–405.
    CrossRefPubMed
  6. Lin CH, Kuo KT, Chuang SS, et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res. 2006; 12(4): 1152–1156.
    CrossRefPubMed
  7. Deckert M, Brunn A, Montesinos-Rongen M, et al. Absence of lymphatic vessels in PCNSL may contribute to confinement of tumor cells to the central nervous system. J Neuropathol Exp Neurol. 2016; 75(6): 499–502.
    CrossRefPubMed
  8. Citterio G, Reni M, Gatta G, et al. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017; 113: 97–110.
    CrossRefPubMed
  9. Sierra del Rio M, Rousseau A, Soussain C, et al. Primary CNS lymphoma in immunocompetent patients. Oncologist. 2009; 14(5): 526–539.
    CrossRefPubMed
  10. Lister A, Abrey LE, Sandlund JT. Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program. 2002: 283–296.
    CrossRefPubMed
  11. Lu JQ, O'Kelly C, Girgis S, et al. Neuroinflammation preceding and accompanying primary central nervous system lymphoma: case study and literature peview. World Neurosurg. 2016; 88: 692.e1–692.e8.
    CrossRefPubMed
  12. Constantin G. Chemokine signaling and integrin activation in lymphocyte migration into the inflamed brain. J Neuroimmunol. 2008; 198(1-2): 20–26.
    CrossRefPubMed
  13. Venetz D, Ponzoni M, Schiraldi M, et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int J Cancer. 2010; 127(10): 2300–2312.
    CrossRefPubMed
  14. Ponzoni M, Berger F, Chassagne-Clement C, et al. International Extranodal Lymphoma Study Group. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol. 2007; 138(3): 316–323.
    CrossRefPubMed
  15. Chang C, Lin CH, Cheng AL, et al. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology. 2015; 67(5): 625–635.
    CrossRefPubMed
  16. Fischer L, Martus P, Weller M, et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008; 71(14): 1102–1108.
    CrossRefPubMed
  17. Izquierdo C, Velasco R, Vidal N, et al. Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. Neuro Oncol. 2016; 18(5): 707–715.
    CrossRefPubMed
  18. Citterio G, Reni M, Ferreri AJ. Present and future treatment options for primary CNS lymphoma. Expert Opin Pharmacother. 2015; 16(17): 2569–2579.
    CrossRefPubMed
  19. Tang YZ, Booth TC, Bhogal P, et al. Imaging of primary central nervous system lymphoma. Clin Radiol. 2011; 66(8): 768–777.
    CrossRefPubMed
  20. Toh CH, Wei KC, Chang CN, et al. Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol. 2013; 34(6): 1145–1149.
    CrossRefPubMed
  21. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002; 59(10): 1557–1562.
    CrossRefPubMed
  22. Adachi K, Yamaguchi F, Node Y, et al. Neuroimaging of primary central nervous system lymphoma in immunocompetent patients: comparison of recent and previous findings. J Nippon Med Sch. 2013; 80(3): 174–183.
    CrossRefPubMed
  23. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011; 117(11): 3140–3146.
    CrossRefPubMed
  24. Davies KG, Cole GC, Weeks RD. Twenty-year survival following excision of primary CNS lymphoma without radiation therapy: case report. Br J Neurosurg. 1994; 8(4): 487–491.
    CrossRefPubMed
  25. Sonstein W, Tabaddor K, Llena JF. Solitary primary CNS lymphoma: long term survival following total resection. Med Oncol. 1998; 15(1): 61–65.
    CrossRefPubMed
  26. Trapella G, Fabi S, Migliore A, et al. Primary central nervous system lymphoma: a case of long survival. Ital J Neurol Sci. 1988; 9(3): 275–278.
    CrossRefPubMed
  27. Holdhoff M. Role of surgical resection in primary CNS lymphoma: a resurrected discussion. Oncology (Williston Park). 2014; 28(7): 641–642.
    PubMed
  28. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115(1): 3–8.
    CrossRefPubMed
  29. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95(2): 190–198.
    CrossRefPubMed
  30. Laws ER, Parney IF, Huang W, et al. Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003; 99(3): 467–473.
    CrossRefPubMed
  31. Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery. 2005; 57(3): 495–504; discussion 495.
    CrossRefPubMed
  32. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010; 11(11): 1036–1047.
    CrossRefPubMed
  33. Weller M, Martus P, Roth P, et al. German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol. 2012; 14(12): 1481–1484.
    CrossRefPubMed
  34. Bellinzona M, Roser F, Ostertag H, et al. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005; 31(1): 100–105.
    CrossRefPubMed
  35. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000; 92(2): 261–266.
    CrossRefPubMed
  36. Jahr G, Da Broi M, Holte H, et al. The role of surgery in intracranial PCNSL. Neurosurg Rev. 2018; 41(4): 1037–1044.
    CrossRefPubMed
  37. Tomlinson FH, Kurtin PJ, Suman VJ, et al. Primary intracerebral malignant lymphoma: a clinicopathological study of 89 patients. J Neurosurg. 1995; 82(4): 558–566.
    CrossRefPubMed
  38. Reni M, Ferreri AJ, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol. 1997; 8(3): 227–234.
    CrossRefPubMed
  39. Henry JM, Heffner RR, Dillard SH, et al. Primary malignant lymphomas of the central nervous system. Cancer. 1974; 34(4): 1293–1302, doi: 10.1002/1097-0142(197410)34:4<1293::aid-cncr2820340441>3.0.co;2-p.
    PubMed
  40. DeAngelis LM, Yahalom J, Heinemann MH, et al. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology. 1990; 40(1): 80–86.
    CrossRefPubMed
  41. Deyo RA, Mirza SK, Martin BI, et al. Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. JAMA. 2010; 303(13): 1259–1265.
    CrossRefPubMed
  42. Patil PG, Turner DA, Pietrobon R. National trends in surgical procedures for degenerative cervical spine disease: 1990-2000. Neurosurgery. 2005; 57(4): 753–8; discussion 753.
    PubMed
  43. Cheney FW, Posner KL, Lee LA, et al. Trends in anesthesia-related death and brain damage: A closed claims analysis. Anesthesiology. 2006; 105(6): 1081–1086.
    CrossRefPubMed
  44. Schebesch KM, Hoehne J, Hohenberger C, et al. Fluorescein sodium-guided surgery in cerebral lymphoma. Clin Neurol Neurosurg. 2015; 139: 125–128.
    CrossRefPubMed
  45. Cheney FW, Posner KL, Lee LA, et al. Trends in anesthesia-related death and brain damage: a closed claims analysis. Anesthesiology. 2006; 105(6): 1081–1086.
    CrossRefPubMed
  46. Cloney MB, Sonabend AM, Yun J, et al. The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. J Neurooncol. 2017; 132(1): 189–197.
    CrossRefPubMed
  47. Corry J, Smith JG, Wirth A, et al. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998; 41(3): 615–620.
    CrossRefPubMed
  48. Koriyama S, Nitta M, Shioyama T, et al. Intraoperative flow cytometry enables the differentiation of primary central nervous system lymphoma from glioblastoma. World Neurosurg. 2018; 112: e261–e268.
    CrossRefPubMed
  49. DeAngelis LM, Yahalom J, Heinemann MH, et al. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology. 1990; 40(1): 80–86.
    CrossRefPubMed
  50. Herrlinger U, Schabet M, Eichhorn M, et al. Prolonged corticosteroid-induced remission in primary central nervous system lymphoma: report of a case and review of the literature. Eur Neurol. 1996; 36(4): 241–243.
    CrossRefPubMed
  51. Moalli PA, Rosen ST. Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymphoma. 1994; 15(5-6): 363–374.
    CrossRefPubMed
  52. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992; 52(19): 5407–5411.
    PubMed
  53. Önder E, Arıkök AT, Önder S, et al. Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability. Int J Clin Exp Pathol. 2015; 8(7): 7798–7808.
    PubMed
  54. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol. 1999; 43(3): 237–239.
    CrossRefPubMed
  55. Patrick LB, Mohile NA. Advances in primary central nervous system lymphoma. Curr Oncol Rep. 2015; 17(12): 60.
    CrossRefPubMed
  56. Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids. Cancer. 2006; 106(2): 383–387.
    CrossRefPubMed
  57. Yamaguchi S, Hirata K, Kaneko S, et al. Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation. Acta Neurochir (Wien). 2015; 157(2): 187–194.
    CrossRefPubMed
  58. Bromberg JEC, Siemers MD, Taphoorn MJB. Is a "vanishing tumor" always a lymphoma? Neurology. 2002; 59(5): 762–764.
    CrossRefPubMed
  59. Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003; 21(24): 4489–4495.
    CrossRefPubMed
  60. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003; 101(2): 466–468.
    CrossRefPubMed
  61. Rubenstein JL, Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013; 121(5): 745–751.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Acta Haematologica Polonica

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice